364 related articles for article (PubMed ID: 28754817)
1. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
2. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
3. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
4. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
5. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
6. The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8
Frey AB
Cancer Immunol Res; 2017 Oct; 5(10):920-928. PubMed ID: 28874354
[TBL] [Abstract][Full Text] [Related]
7. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
Derré L; Rivals JP; Jandus C; Pastor S; Rimoldi D; Romero P; Michielin O; Olive D; Speiser DE
J Clin Invest; 2010 Jan; 120(1):157-67. PubMed ID: 20038811
[TBL] [Abstract][Full Text] [Related]
8. PD-1
Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Szomolay B; Ott S; Dolton G; Lyngaa R; Hadrup SR; Sewell AK; Svane IM
Clin Cancer Res; 2017 Oct; 23(19):5779-5788. PubMed ID: 28679768
[No Abstract] [Full Text] [Related]
9. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
10. BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties.
Haymaker CL; Wu RC; Ritthipichai K; Bernatchez C; Forget MA; Chen JQ; Liu H; Wang E; Marincola F; Hwu P; Radvanyi LG
Oncoimmunology; 2015 Aug; 4(8):e1014246. PubMed ID: 26405566
[TBL] [Abstract][Full Text] [Related]
11. Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis.
Shitaoka K; Hamana H; Kishi H; Hayakawa Y; Kobayashi E; Sukegawa K; Piao X; Lyu F; Nagata T; Sugiyama D; Nishikawa H; Tanemura A; Katayama I; Murahashi M; Takamatsu Y; Tani K; Ozawa T; Muraguchi A
Cancer Immunol Res; 2018 Apr; 6(4):378-388. PubMed ID: 29475880
[TBL] [Abstract][Full Text] [Related]
12. Hepatic expansion of virus-specific CD8
Wang H; Wu B; Li L; Hu L; Lin J; Jiang C; Cai G; Shen Q
Cell Immunol; 2017 Jan; 311():36-45. PubMed ID: 27743606
[TBL] [Abstract][Full Text] [Related]
13. MERTK Acts as a Costimulatory Receptor on Human CD8
Peeters MJW; Dulkeviciute D; Draghi A; Ritter C; Rahbech A; Skadborg SK; Seremet T; Carnaz Simões AM; Martinenaite E; Halldórsdóttir HR; Andersen MH; Olofsson GH; Svane IM; Rasmussen LJ; Met Ö; Becker JC; Donia M; Desler C; Thor Straten P
Cancer Immunol Res; 2019 Sep; 7(9):1472-1484. PubMed ID: 31266785
[TBL] [Abstract][Full Text] [Related]
14. Expansion of Tumor-Infiltrating CD8
Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
[TBL] [Abstract][Full Text] [Related]
15. IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells.
Parrot T; Allard M; Oger R; Benlalam H; Raingeard de la Blétière D; Coutolleau A; Preisser L; Desfrançois J; Khammari A; Dréno B; Labarrière N; Delneste Y; Guardiola P; Gervois N
Eur J Immunol; 2016 Jul; 46(7):1770-82. PubMed ID: 27094152
[TBL] [Abstract][Full Text] [Related]
16. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
[TBL] [Abstract][Full Text] [Related]
17. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function.
Serriari NE; Gondois-Rey F; Guillaume Y; Remmerswaal EB; Pastor S; Messal N; Truneh A; Hirsch I; van Lier RA; Olive D
J Immunol; 2010 Sep; 185(6):3140-8. PubMed ID: 20693422
[TBL] [Abstract][Full Text] [Related]
18. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
[TBL] [Abstract][Full Text] [Related]
19. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of B and T lymphocyte attenuator engagement on CD4+ and CD8+ T cells.
Krieg C; Han P; Stone R; Goularte OD; Kaye J
J Immunol; 2005 Nov; 175(10):6420-7. PubMed ID: 16272294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]